# Safety and Effectivness of Quercetin & Dasatinib on Epigenetic Aging

> **NCT04946383** · PHASE2 · UNKNOWN · sponsor: **TruDiagnostic** · enrollment: 25 (estimated)

## Conditions studied

- Aging

## Interventions

- **DRUG:** Dasatinib plus Quercetin

## Key facts

- **NCT ID:** NCT04946383
- **Lead sponsor:** TruDiagnostic
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-16
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-06-30
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2021-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04946383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04946383, "Safety and Effectivness of Quercetin & Dasatinib on Epigenetic Aging". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04946383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*